Sanofi Says U.S. Waiting Period for Bioverativ Has Expired

   By Sonia Amaral Rohter 
 

Sanofi SA (SAN.FR) said on Friday that a U.S. waiting period for its proposed acquisition of Bioverativ Inc. (BIVV) has expired without objections.

With the expiration, "the condition to the offer relating to antitrust approvals has been satisfied," Sanofi said.

The waiting period--a notification program under the U.S. Hart-Scott-Rodino Antitrust Improvements Act--requires parties to certain transactions to submit notification to the U.S. Federal Trade Commission and Department of Justice and wait before the transaction can be completed.

In January, Sanofi agreed to buy hemophilia drug maker Bioverativ for approximately $11.6 billion. On Feb. 7, Sanofi commenced the tender offer, which is scheduled to expire on March 7.

The closing of the offer is still subject to various conditions, Sanofi said.

Write to Sonia Amaral Rohter at [e-mail]

(END) Dow Jones Newswires

February 23, 2018 06:29 ET (11:29 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.